focus -WSS

focus

author：leisure time 2025-10-06 17:54:30 - browse：698

After months of vigorous deliberations, I’m thrilled to announce our 2023 STATUS List — the definitive roster of leaders in health, medicine, and the life sciences whose work over the past year has advanced those fields.

There were, of course, many contenders to choose from. For this second annual list, we’ve selected just 46 — an homage to the number of chromosomes in human DNA. Many are well-known as changemakers; others are largely unheralded heroes. They are CEOs, philanthropists, government officials, and health advocates. All have compelling stories to tell.

Our editorial team painstakingly researched and identified hundreds of finalists. In winnowing down the list, judges placed special emphasis on people who have sought to help others and build community in these often-divisive times. One note: Our news coverage is independent of this list, and we remain committed to tough-minded reporting on the people and institutions shaping life sciences.

While I have your attention, I want to point you to some of our most talked-about exclusive stories in recent days: A new STAT investigation exposes how Medicare Advantage plans use algorithms to cut off care for seniors in need, and we took a closer look at how a Medicare Advantage business is strangling one of its first funders. We’re aggressively reporting on the consequences for biotech of the Silicon Valley Bank collapse.

And over the coming months, in our series “The Obesity Revolution,” we’ll explore a class of obesity drugs that is transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years.

For full access to our exclusive reporting, please consider purchasing a STAT+ subscription. Get 15% off an annual subscription by using promo code STAT15 when you check out.

As always, please reach out to me with feedback. I’m at [email protected].

Previous article： Cancer drug shortages should be causing more outrage
Next article： Anavex keeps shifting the goalposts in its clinical trials

hotspot

WSS

Fentanyl is making it harder to start addiction treatment

American woman, child freed after being kidnapped in Haiti last month

In same hospitals, Black patients receive fewer opioids than white patients

Liver decline slowed by off

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

American woman, child freed after being kidnapped in Haiti last month

hotspot

focus

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Cue Health, Covid

Sports medicine is finally prioritizing gender equality

Naloxone nonprofit donates 200,000 doses after FDA approval

In Memoriam: Notable people who died in 2023

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

In Memoriam: Notable people who died in 2023

NIH trials fail to test meaningful long Covid therapies, experts say

Moonlake's readout produced a cash windfall. Risks remain

FDA poised to publish guidelines for clinical trial diversity

entertainment

Wegovy’s successful heart trial raises vital question about weight loss

A biotech analyst on neuroscience, placebo effect, not over

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Questions and answers about ramping up H5N1 bird flu vaccine

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

ASCO eve: Let’s set the table for this year's meeting

focus

Wikipedia

hotspot

focus